State Street SPDR Bloomberg High Yield Bond ETF vs Regeneron Pharmaceuticals Inc — how do they compare? State Street SPDR Bloomberg High Yield Bond ETF trades at $95.87, while Regeneron Pharmaceuticals Inc trades at $792.58 (market cap $82.06B). The key difference: Regeneron Pharmaceuticals Inc pays a 0.47% dividend while State Street SPDR Bloomberg High Yield Bond ETF pays none, and Regeneron Pharmaceuticals Inc is trading nearer its 52-week high, State Street SPDR Bloomberg High Yield Bond ETF nearer its low. Which is the better fit depends on your goals.
| JNK | REGN | |
|---|---|---|
Sector | Fixed Income | Health |
52-Week High | $98.19 | $812.27 |
52-Week Low | $94.66 | $555.51 |
Market Cap | — | $82.06B |
Enterprise Value | — | $76.77B |
Dividend Yield | — | 0.47% |
Signals from Pluang's Aura AI — not financial advice
JNK trades at $95.845, up 0.2% today, with a bearish technical outlook indicated by moving averages and ADX signals. Recent news highlights risks from AI-related corporate debt and rising Treasury yields, while dividend payments provide income. The ETF faces headwinds from inflation and geopolitical tensions affecting bond markets.
The outlook is cautious due to credit market risks and Fed uncertainty. Opportunities exist for yield-seeking investors, but volatility from oil prices and rate hikes poses significant risks. Monitoring economic data and corporate credit health is essential for navigating near-term performance.
Regeneron Pharmaceuticals (REGN) trades at $808.05, up 3.02% today, with strong technical momentum and bullish moving averages. The company shows robust fundamentals: Q2 2026 EPS of $14.29 beat expectations by over 40%, revenue grew to $14.34B in 2025, and profit margins exceed 27%. However, RSI levels above 95 indicate overbought conditions, and the stock faces headwinds from multiple class-action lawsuits related to clinical trial disclosures.
Outlook remains positive due to earnings beats and product strength in Eylea HD and Dupixent, but legal overhangs and high valuation multiples pose near-term risks. Analysts maintain a Buy consensus with a $756.93 price target, suggesting cautious optimism amid legal scrutiny.
Trailing returns across standard periods
JNK is a major ETF tracking the Bloomberg High Yield Very Liquid Index. It provides exposure to U.S. dollar-denominated junk bonds with above-average liquidity, featuring 2026 top holdings like EchoStar, Cloud Software Group, and Carnival Corp.
Read more on JNK →Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →